IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that the Cámara Industrial de Laboratorios Farmacéuticos Argentinos (CILFA) has been accepted and welcomed as a new IGBA Associate Member.
“The International Generic and Biosimilar medicines Association (IGBA) invites generic and biosimilar medicines manufacturers to actively engage and commit to contributing to the global manufacturing capacity once an existing or newly-discovered therapeutic is proven to be effective against COVID-19.
IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today pays tribute to Bill Haddadi, who passed away last week. He was a pioneer in the development of generic medicine policy in the U.S.A. and a remarkable advocate for access to medicines worldwide.
- ACCESS TO COVID-19 TOOLS (ACT) ACCELERATOR” - IGBA is Joining Forces on Global Collaboration to Overcome COVID-19 (24 April 2020)
- IGBA Contributes to Global Discussion on Tailored Clinical Biosimilar Development with New Peer-Reviewed Scientific Paper (10 April 2020)
- COVID-19: IGBA calls for urgent priority designation for medicines at custom controls and for cargo and freight (6 April 2020)
- COVID-19: IGBA urgent recommendations to keep medicine supply chains flowing (27 March 2020)